REmote SUpport for Low-Carbohydrate Treatment of type2 diabetes:RESULT

  • Research type

    Research Study

  • Full title

    Testing the effectiveness of a low carbohydrate diet with remote support for patients with type 2 diabetes in primary care, on weight and glycaemic control: a randomised controlled trial

  • IRAS ID

    295974

  • Contact name

    Paul Aveyard

  • Contact email

    paul.aveyard@phc.ox.ac.uk

  • Sponsor organisation

    University of Oxford

  • Clinicaltrials.gov Identifier

    NCT04916314

  • Duration of Study in the UK

    2 years, 5 months, 1 days

  • Research summary

    The standard for diabetes management is changing. What was previously thought to be a lifelong progressive condition to be managed primarily with increasing doses of medications, may instead be put into remission (achieving normal or near-normal blood glucose levels without medications) if treated with intensive weight loss support. However, the majority of patients with type 2 diabetes still rely on general dietary advice from primary care professionals. While there is considerable uncertainty regarding the optimal diet composition for people with type 2 diabetes, there is a growing interest from patients, practitioners and the general public in using real-food, low carbohydrate diets to achieve weight loss, improved glycaemic control and even disease remission. A recent small-scale study demonstrated that it was possible, and effective in the short-term, for practice nurses in primary care to support patients with type 2 diabetes to adopt a real-food, low-carbohydrate weight loss diet. However the patients and healthcare professionals who took part in this study were keen to know whether digital interventions and app-based support could be an alternative way to achieve the same results, with the potential for more frequent support without increasing the demand on the primary care workforce. This study aims to investigate whether an app-based low-carbohydrate intervention with remote behavioural support is effective at improving glycaemia, weight, and other markers of cardiometabolic risk, for people with type 2 diabetes in primary care.

  • REC name

    West Midlands - Solihull Research Ethics Committee

  • REC reference

    21/WM/0101

  • Date of REC Opinion

    28 Apr 2021

  • REC opinion

    Further Information Favourable Opinion